Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Pharmacol Ther ; 242: 108349, 2023 02.
Artículo en Inglés | MEDLINE | ID: mdl-36682466

RESUMEN

Corneal diseases are one of the leading causes of moderate-to-severe visual impairment and blindness worldwide, after glaucoma, cataract, and retinal disease in overall importance. Given its tendency to affect people at a younger age than other blinding conditions such as cataract and glaucoma, corneal scarring poses a huge burden both on the individuals and society. Furthermore, corneal scarring and fibrosis disproportionately affects people in poorer and remote areas, making it a significant ophthalmic public health problem. Traditional medical strategies, such as topical corticosteroids, are not effective in preventing fibrosis or scars. Corneal transplantation, the only effective sight-restoring treatment for corneal scars, is curbed by challenges including a severe shortage of tissue, graft rejection, secondary conditions, cultural barriers, the lack of well-trained surgeons, operating rooms, and well-equipped infrastructures. Thanks to tremendous research efforts, emerging therapeutic options including gene therapy, protein therapy, cell therapy and novel molecules are in development to prevent the progression of corneal scarring and compliment the surgical options currently available for treating established corneal scars in clinics. In this article, we summarise the most relevant preclinical and clinical studies on emerging therapies for corneal scarring in recent years, showing how these approaches may prevent scarring in its early development.


Asunto(s)
Catarata , Enfermedades de la Córnea , Lesiones de la Cornea , Glaucoma , Humanos , Cicatriz/terapia , Cicatriz/complicaciones , Lesiones de la Cornea/terapia , Lesiones de la Cornea/complicaciones , Enfermedades de la Córnea/tratamiento farmacológico , Enfermedades de la Córnea/complicaciones , Glaucoma/complicaciones , Catarata/complicaciones
2.
Adv Exp Med Biol ; 1383: 319-328, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36587169

RESUMEN

Many gastrointestinal motility disorders arise due to defects in the enteric nervous system. Achalasia and gastroparesis are two extremely debilitating digestive diseases of the upper gastrointestinal tract caused in part by damage or loss of the nitrergic neurons in the esophagus and stomach. Most current pharmacological and surgical interventions provide no long-term relief from symptoms, and none address the cause. Stem cell therapy, to replace the missing neurons and restore normal gut motility, is an attractive alternative therapy. However, there are a number of hurdles that must be overcome to bring this exciting research from the bench to the bedside.


Asunto(s)
Sistema Nervioso Entérico , Enfermedades Gastrointestinales , Gastroparesia , Humanos , Motilidad Gastrointestinal/fisiología , Enfermedades Gastrointestinales/terapia , Gastroparesia/terapia , Tratamiento Basado en Trasplante de Células y Tejidos , Tracto Gastrointestinal
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...